For CD80, the role of the tumor microenvironment cannot be ruled out since CD80 is expressed on the surface of tumor-associated macrophages (TAM) and the inhibition of CD80-CD28 interaction by galiximab interferes with TAM-mediated cytokine responses and proangiogenic signals, all of which induce antitumor activity (8). This evidence concerns the gene CD80 and neoplasm.